Abstract:Background: Platelets, a type of anucleated cell, play a crucial role in cardiovascular diseases (CVDs). Therefore, targeting platelet activation is essential for mitigating CVDs. Endogenous agonists, such as collagen, activate platelets by initiating signal transduction through specific platelet receptors, leading to platelet aggregation. Eugenol, primarily sourced from clove oil, is known for its antibacterial, anticancer, and anti-inflammatory properties, making it a valuable medicinal agent. In our previous study, eugenol was shown to inhibit platelet aggregation induced by collagen and arachidonic acid. We concluded that eugenol exerts a potent inhibitory effect on platelet activation by targeting the PLCγ2-PKC and cPLA2-TxA2 pathways, thereby suppressing platelet aggregation. In our current study, we found that eugenol significantly inhibits NF-κB activation. This led us to investigate the relationship between the NF-κB and cPLA2 pathways to elucidate how eugenol suppresses platelet activation. Methods: In this study, we prepared platelet suspensions from the blood of healthy human donors to evaluate the inhibitory mechanisms of eugenol on platelet activation. We utilized immunoblotting and confocal microscopy to analyze these mechanisms in detail. Additionally, we assessed the anti-thrombotic effect of eugenol by observing fluorescein-induced platelet plug formation in the mesenteric microvessels of mice. Results: For immunoblotting and confocal microscopy studies, eugenol significantly inhibited NF-κB-mediated signaling events stimulated by collagen in human platelets. Specifically, it reduced the phosphorylation of IKK and p65 and prevented the degradation of IκBα. Additionally, CAY10502, a cPLA2 inhibitor, significantly reduced NF-κB-mediated signaling events. In contrast, BAY11-7082, an IKK inhibitor, did not affect collagen-stimulated cPLA2 phosphorylation. These findings suggest that cPLA2 acts as an upstream regulator of NF-κB activation during platelet activation. Furthermore, both BAY11-7082 and CAY10502 significantly reduced the collagen-induced rise in intracellular calcium levels. In the animal study, eugenol demonstrated potential as an anti-thrombotic agent by significantly reducing platelet plug formation in fluorescein-irradiated mouse mesenteric microvessels. Conclusion: Our study uncovered a novel pathway in platelet activation involving the cPLA2-NF-κB axis, which plays a key role in the antiplatelet effects of eugenol. These findings suggest that eugenol could serve as a valuable and potent prophylactic or therapeutic option for arterial thrombosis.

A CAPE Analogue As Novel Antiplatelet Agent Efficiently Inhibits Collagen-Induced Platelet Aggregation.

Structure-Antiplatelet Activity Relationships of Novel Ruthenium (II) Complexes: Investigation of Its Molecular Targets

N-acetylcysteine Amide AD4/NACA and Thioredoxin Mimetic Peptides Inhibit Platelet Aggregation and Protect against Oxidative Stress

Brazilin isolated from Caesalpinia sappan L. acts as a novel collagen receptor agonist in human platelets

Comparison of Collagen Versus Adenosine Diphosphate in Detecting Antiplatelet Effect in Patients with Coronary Artery Disease.

Protection of CAPE-pNO2 Against Chronic Myocardial Ischemia by the TGF-Β1/Galectin-3 Pathway In Vivo and In Vitro

A novel di-peptide Met-Glu from collagen hydrolysates inhibits platelet aggregation and thrombus formation via regulation of Gq-mediated signaling

Inhibition of Platelet Adhesion to Exposed Subendothelial Collagen by Steric Hindrance with Blocking Peptide Nanoparticles

Anti-colon Cancer Effect of Caffeic Acid P-Nitro-phenethyl Ester in Vitro and in Vivo and Detection of Its Metabolites.

Inhibited Effects of CAPE-pNO2 on Cervical Carcinoma in Vivo and in Vitro and Its Detected Metabolites

Antiplatelet effects of the CEACAM1-derived peptide QDTT

[Effects of 2A-1-1 on the Aggregation and Ca2+ Influx of Platelets].

Design, Synthesis, and Evaluation of the Novel Ozagrel-Paeonol Codrug with Antiplatelet Aggregation Activities As a Potent Anti-Stroke Therapeutic Agent

Eugenol: A Potential Modulator of Human Platelet Activation and Mouse Mesenteric Vascular Thrombosis via an Innovative cPLA2-NF-κB Signaling Axis

Inhibition of Platelet Aggregation by Polyaspartoyl L-Arginine and Its Mechanism

Ginkgetin effectively mitigates collagen and AA‐induced platelet activation via PLCγ2 but not cyclic nucleotide‐dependent pathway in human

Plant-based Food Cyanidin-3-Glucoside Modulates Human Platelet Glycoprotein VI Signaling and Inhibits Platelet Activation and Thrombus Formation

Prostaglandin A1 Inhibits Increases in Intracellular Calcium Concentration, TXA2 Production and Platelet Activation1

Caffeic Acid Phenethyl Ester Inhibits the Progression of Elastase Induced Aortic Aneurysm in Rats

Novel Peptide Motifs Containing Asp-Glu-Gly Target P2Y12 and Thromboxane A2 Receptors to Inhibit Platelet Aggregation and Thrombus Formation

NADPH oxidase 1/4 dual inhibitor setanaxib suppresses platelet activation and thrombus formation